VivoSeq
Hematology

Hematopoietic Stem Cell Transplant (HSCT)

0

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

Hematopoietic Stem Cell Transplant (HSCT) is an early-stage landscape with 0 programs across 3 companies. The most active players are Merck & Co., Takeda, CSL Behring.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalTakeda logo

Takeda

0 programs

PreclinicalCSL Behring logo

CSL Behring

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed4 · 40%
Recruiting4 · 40%
Terminated2 · 20%

Clinical Trials

Trial Activity

10 trials

Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
Recruiting·—·Phase 1·NCT07244419·20 enrolled
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
Recruiting·Takeda logoTakeda·Phase 3·NCT05319353·80 enrolled
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Recruiting·TTr1X, Inc.·Phase 1·NCT06462365·36 enrolled
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
Recruiting·CChildren's Hospital Medical Center, Cincinnati·N/A·NCT04098445·2,000 enrolled
Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT03930615·220 enrolled
Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00565929·24 enrolled
Glutamine Popsicles in Bone Marrow Transplant (BMT)/Hematopoietic Stem Cell Transplant (HSCT) Patients
Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT00204958·50 enrolled
Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone
Completed·CSL Behring logoCSL Behring·Phase 3·NCT04167514·136 enrolled
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT03151057·16 enrolled
A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients
Terminated·National Eye Institute (NEI)·Phase 2·NCT01972438·18 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)